Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
13.99
-0.63 (-4.31%)
At close: Feb 21, 2025, 4:00 PM
13.89
-0.10 (-0.71%)
After-hours: Feb 21, 2025, 7:47 PM EST
Evolus Revenue
Evolus had revenue of $61.09M in the quarter ending September 30, 2024, with 22.12% growth. This brings the company's revenue in the last twelve months to $248.33M, up 34.43% year-over-year. In the year 2023, Evolus had annual revenue of $202.09M with 35.98% growth.
Revenue (ttm)
$248.33M
Revenue Growth
+34.43%
P/S Ratio
3.41
Revenue / Employee
$909,619
Employees
273
Market Cap
885.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
EOLS News
- 2 days ago - Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - Business Wire
- 4 days ago - Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - Business Wire
- 9 days ago - US FDA approves Evolus' anti-wrinkle gels - Reuters
- 9 days ago - Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Business Wire
- 15 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance - Business Wire
- 5 weeks ago - Evolus: Still Bullish, But Business Faces Tricky Challenges In '25 - Seeking Alpha
- 3 months ago - Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha